tiprankstipranks
Allogene Therapeutics: Strategic Cash Management and ALPHA3 Potential Drive Buy Rating Amid Clinical Delays
PremiumRatingsAllogene Therapeutics: Strategic Cash Management and ALPHA3 Potential Drive Buy Rating Amid Clinical Delays
2M ago
Allogene Therapeutics price target lowered to $10 from $14 at Truist
Premium
The Fly
Allogene Therapeutics price target lowered to $10 from $14 at Truist
2M ago
Allogene Therapeutics price target lowered to $9 from $10 at Oppenheimer
Premium
The Fly
Allogene Therapeutics price target lowered to $9 from $10 at Oppenheimer
2M ago
Allogene downgraded to Market Perform from Outperform at Citizens JMP
PremiumThe FlyAllogene downgraded to Market Perform from Outperform at Citizens JMP
2M ago
Allogene Therapeutics Advances Clinical Trials and Extends Cash Runway
Premium
Company Announcements
Allogene Therapeutics Advances Clinical Trials and Extends Cash Runway
2M ago
Allogene Therapeutics reports Q1 EPS (28c), consensus (29c)
Premium
The Fly
Allogene Therapeutics reports Q1 EPS (28c), consensus (29c)
2M ago
Allogene Therapeutics: Buy Rating Backed by Promising Pipeline Developments and Strong Financial Position
PremiumRatingsAllogene Therapeutics: Buy Rating Backed by Promising Pipeline Developments and Strong Financial Position
4M ago
Allogene Therapeutics price target lowered to $8 from $9 at H.C. Wainwright
Premium
The Fly
Allogene Therapeutics price target lowered to $8 from $9 at H.C. Wainwright
4M ago
Allogene Therapeutics management to meet virtually with Truist
Premium
The Fly
Allogene Therapeutics management to meet virtually with Truist
4M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100